Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 1/20 | 0.43 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 6/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | BRS3 | P32247 | 1/20 | 0.34 |
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4985337 | 0.85 | DHFR (0.52) | LIMK1DHFRBRS3 | |
| SCHEMBL4987940 | 0.84 | ALDH1A1 (0.47) | LIMK1PDE2A | |
| SCHEMBL4986800 | 0.84 | KDM4E (0.44) | LIMK1DHFRMEN1KMT2A | |
| SCHEMBL4988556 | 0.83 | LIMK1 (0.47) | LIMK1GRM2MEN1KMT2ABRS3 | |
| SCHEMBL4989378 | 0.83 | LIMK1 (0.51) | LIMK1DHFRMEN1KMT2A | |
| SCHEMBL4980826 | 0.82 | HRH3 (0.47) | LIMK1KMT2A | |
| SCHEMBL4992362 | 0.82 | LIMK1 (0.48) | LIMK1MEN1KMT2A | |
| SCHEMBL4989371 | 0.81 | LIMK1 (0.47) | LIMK1MEN1KMT2APOLB | |
| SCHEMBL4992461 | 0.81 | LIMK1 (0.47) | LIMK1DHFRMEN1KMT2A | |
| SCHEMBL4982960 | 0.80 | LIMK1 (0.61) | LIMK1DHFRMEN1KMT2ABRS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
| US-7297700-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2007-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | LIMK1 1960/4885PDE2A 1483/4885GRM2 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.